Aurora-A is a member of the serine/threonine kinases family that are important mitotic regulators. It is involved in centrosome function, mitotic entry, and spindle assembly. Breast cancer 2, early onset (BRCA2), plays an important role in maintaining genomic stability and acts as a tumor suppressor gene. The aim of this study is to evaluate the relationship between Aurora-A and BRCA2 proteins’ expression and the prognostic clinicopathological factors of serous ovarian carcinoma.
Thirty-four blocks from serous ovarian carcinoma patients were analyzed for Aurora-A and BRCA2 proteins’ expression by immunohistochemistry. The results were studied in relation to the known prognostic clinicopathological features in serous ovarian carcinoma.
Nuclear and cytoplasmic Aurora-A immunoreactivity was found in 41.2 and 44.1% of cases, respectively, whereas BRCA2 positivity was found in 20.6% of cases. No relationship was found between Aurora-A protein expression (nuclear or cytoplasmic) and age of the patients, family history of ovarian cancer, or tumor grade. A significant relationship was found between tumor stage and Aurora-A protein expression. A significant relationship was found between serum level of CA125 and nuclear Aurora-A protein expression. BRCA2 protein expression was associated significantly with a family history of ovarian tumors, tumor grade, and stage, but not with patient age or serum level of CA125. The 5-year overall survival and disease-free survival were inversely related to Aurora-A immunoreactivity and positively related to BRCA2 expression. We found an inverse correlation between BRCA2 and Aurora-A protein expression
Aurora-A expression is a marker of poor prognosis in patients with serous ovarian carcinoma, whereas BRCA2 is a marker of good prognosis. The negative correlation between Aurora-A and BRCA2 represents a potential prognostic marker for serous ovarian carcinoma.
Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Correspondence to Eman H. Abdel-Bary, Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt Tel: +201 227 088 801; e-mail: email@example.com
Received January 15, 2013
Accepted March 1, 2013